Regulatory
Vaccine expert Rick Bright, who was abruptly dismissed from his post as director of the Biomedical Advanced Research and Development Authority (BARDA) last month, filed a whistleblower complaint against the administration over its failures to heed warnings about the COVID-19 pandemic and accused the White House of cronyism in awarding contracts.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
The U.S. Federal Trade Commission gave the green light to the $63 billion merger of AbbVie and Allergan. That leaves one last hurdle for the two companies, approval from the Irish High Court.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
The U.S. Food and Drug Administration (FDA) approved Gilead’s remdesivir under Emergency Use Authorization as a treatment for COVID-19 following reports the drug met its primary endpoint in a U.S. National Institute of Allergy and Infectious Diseases (NIAID) clinical trial.
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
Zejula, GlaxoSmithKline’s once-daily PARP inhibitor, won regulatory approval as a monotherapy maintenance treatment for women with advanced ovarian cancer whose disease is responsive to first-line platinum-based chemotherapy, regardless of biomarker status.
PRESS RELEASES